Trial Profile
Dapagliflozin During Exercise for the Prevention of Hypoglycaemia in Type 1 Diabetes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Exercise-induced hypoglycaemia; Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DEPTH
- 22 May 2022 Status changed from suspended to discontinued.
- 04 Nov 2020 Planned End Date changed from 22 Dec 2018 to 22 Dec 2021.
- 04 Nov 2020 Planned primary completion date changed from 22 Dec 2018 to 22 Dec 2021.